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Interim Infection Prevention and Control Recommendations for Hospitalized Patients 
with Middle East Respiratory Syndrome Coronavirus (MERS-CoV) 
Standard, contact, and airborne precautions are recommended for management of hospitalized patients with 
known or suspected MERS-CoV infection, based on CDC's case definition for a patient under investigation: 
www.cdc.gov/coronavirus/mers/case-def.html#pui. Note that additional infection prevention precautions or 
considerations may be needed if a MERS-CoV patient has other conditions or illnesses that warrant specific 
measures (e.g., tuberculosis, Clostridium difficile, multi-drug resistant organisms). 
Though these recommendations focus on the hospital setting, the recommendations for personal protective 
equipment (PPE), source control (i.e., placing a facemask on potentially infected patients when outside of an 
airborne infection isolation room), and environmental infection control measures are applicable to any 
healthcare setting.  
In this guidance healthcare personnel (HCP) refers all persons, paid and unpaid, working in healthcare settings 
who have the potential for exposure to patients and/or to infectious materials, including body substances, 
contaminated medical supplies and equipment, contaminated environmental surfaces, or contaminated air. HCP 
include, but are not limited to, physicians, nurses, nursing assistants, therapists, technicians, emergency medical 
service personnel, dental personnel, pharmacists, laboratory personnel, autopsy personnel, students and 
trainees, contractual personnel, home healthcare personnel, and persons not directly involved in patient care 
(e.g., clerical, dietary, house-keeping, laundry, security, maintenance, billing, chaplains, and volunteers) but 
potentially exposed to infectious agents that can be transmitted to and from HCP and patients. This guidance is 
not intended to apply to persons outside of healthcare settings.   
As information becomes available, these recommendations will be re-evaluated and updated as needed. These 
recommendations are based upon available information (as of May 14, 2014) and the following considerations: 
 Suspected high rate of morbidity and mortality among infected patients  
 Evidence of limited human-to-human transmission 
 Poorly characterized clinical signs and symptoms 
 Unknown modes of transmission of MERS-CoV 
 Lack of a vaccine and chemoprophylaxis 
Key Components of Standard, Contact, and Airborne Precautions Recommended for Prevention of 
MERS-CoV Transmission in U.S. Hospitals 
For full details of these precautions, see 2007 Guideline for Isolation Precautions: Preventing Transmission of 
Infectious Agents in Healthcare Setting: www.cdc.gov/hicpac/2007IP/2007isolationPrecautions.html. 
Component Recommendation(s) Comments 
Patient 
placement 
 Airborne Infection Isolation Room (AIIR)  If an AIIR is not available, the patient 
should be transferred as soon as is 
feasible to a facility where an AIIR is 
available. Pending transfer, place a 
facemask on the patient and isolate 
him/her in a single-patient room 
with the door closed. The patient 
should not be placed in any room 
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Component Recommendation(s) Comments 
where room exhaust is recirculated 
without high-efficiency particulate 
air (HEPA) filtration. 
 Once in an AIIR, the patient’s 
facemask may be removed.  
 When outside of the AIIR, patients 
should wear a facemask to contain 
secretions. 
 Limit transport and movement of the 
patient outside of the AIIR to 
medically-essential purposes. 
 Implement staffing policies to 
minimize the number of personnel 
that must enter the patient’s room. 
 After a potentially infectious patient 
leaves a room, unprotected 
individuals, including HCP, should 
not be allowed in the room until 
sufficient time has elapsed for 
enough air changes to remove 
potentially infectious particles. More 
information on clearance rates 








 Use a combination of measures to reduce 
exposures from aerosol-generating procedures 
when performed on MERS-CoV patients. 
 Limiting the number of HCP present during the 
procedure to only those essential for patient 
care and support. 
 Conduct the procedures in a private room and 
ideally in an AIIR when feasible. Room doors 
should be kept closed except when entering or 
leaving the room, and entry and exit should be 
minimized during and shortly after the 
procedure.  
 HCP should adhere to PPE precautions in this 
interim guidance (i.e., gloves, a gown, and either 
a face shield that fully covers the front and sides 
of the face or goggles, and respiratory protection 
that is at least as protective as a fit-tested N95 
filtering facepiece respirator  [e.g., powered air 
purifying or elastomeric respirator during 
aerosol-generating procedures]). 
 Conduct environmental surface cleaning 
 Although there are limited data 
available to definitively define a list 
of aerosol generating procedures, 
procedures that are usually included 
are those planned ahead of time, 
such as bronchoscopy, sputum 
induction, elective intubation and 
extubation; and some procedures 
that often occur in unplanned, 
emergent settings and can be life-
saving, such as cardiopulmonary 
resuscitation, emergent intubation, 
and open suctioning of airways. 
 Once the patient vacates a room 
where aerosol generating 
procedures were conducted, 
unprotected individuals, including 
HCP, should not be allowed in that 
room until sufficient time has 
elapsed for enough air changes to 
remove potentially infectious 
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Component Recommendation(s) Comments 
following procedures (see section below on 
environmental infection control). 
particles. More information on 
clearance rates under differing 













 Eye protection (goggles or face shield) 
 Respiratory protection that is at least as 
protective as a fit-tested NIOSH-certified 
disposable N95 filtering facepiece respirator or 
greater.  
o If a respirator is unavailable, a facemask 
should be worn. In this situation 
respirators should be made available as 
quickly as possible. 
 Recommended PPE should be worn 
by HCP upon entry into patient 
rooms or care areas for any reason 
(e.g., clinical care, specimen 
collection, environmental cleaning, 
etc.). 
 Upon exit from the patient room or 
care area, PPE should be removed 
and either  
o Discarded, or 
o For re-useable PPE, cleaned 
and disinfected according to 
the manufacturer’s 
reprocessing instructions 
o Hand hygiene should be 
performed after removal of 
PPE. 
Hand Hygiene  HCP should perform hand hygiene frequently, 
including before and after all patient contact, 
contact with potentially infectious material, and 
before putting on and upon removal of PPE, 
including gloves.  
 Healthcare facilities should ensure that supplies 
for performing hand hygiene are available. 
 Hand hygiene in healthcare settings 
can be performed by washing with 
soap and water or using alcohol-
based hand rubs. If hands are visibly 
soiled, use soap and water, not 




 Follow standard procedures, per hospital policy 
and manufacturers’ instructions, for cleaning 
and/or disinfection of:  
o Environmental surfaces and equipment  
o Textiles and laundry 
o Food utensils and dishware 
 Use EPA-registered hospital 
disinfectants to disinfect hard non-
porous surfaces.  
o Follow label instructions for 
use.  








 At this time, information is lacking to definitively 
determine a recommended duration for keeping 
patients in isolation precautions. 
 Duration of precautions should be determined 
on a case-by-case basis, in conjunction with 
local, state, and federal health authorities.  
 Factors that should be considered 
include: presence of symptoms 
related to MERS-CoV, date 
symptoms resolved, other conditions 
that would require specific 
precautions (e.g., tuberculosis, 
Clostridium difficile) and available 
laboratory information.  
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 HCP who care for patients with MERS-CoV 
should be advised to monitor and immediately 
report any signs or symptoms of acute illness to 
their supervisor or a facility designated person 
(e.g., occupational health services) for a period 
of 14 days after the last known contact with the 
sick patient. 
 HCP who develop respiratory symptoms or fever 
after an unprotected exposure (i.e. not wearing 
recommended PPE at the time of contact) to a 
patient with MERS-CoV should 
o not report to work or immediately stop 
working 
o notify their supervisor  
o implement respiratory hygiene and 
cough etiquette 
o seek prompt medical evaluation 
o comply with work exclusion until they 
are deemed no longer infectious to 
others. 
 For asymptomatic HCP who had an unprotected 
exposure (i.e. not wearing recommended PPE at 
the time of contact) to a patient with MERS-CoV  
o Consider exclusion from work for 14 
days to monitor for signs and symptoms 
of respiratory illness and fever 
o If necessary to ensure adequate staffing 
of the facility the asymptomatic provider 
could be considered for continuing work 
if they wear a facemask for source 
control (i.e., limiting transmission from 
exposed HCP to other HCP or patients), 
 The facemask should be worn at 
all times while in the healthcare 
facility for 14 days from the last 
unprotected exposure 
 HCP continuing to work while 
wearing a facemask should be 
reminded that if caring for 
patients under airborne 
precautions, to change the 
facemask to respiratory 
protection that is at least as 
protective as a fit-tested NIOSH-
certified disposable N95 filtering 
facepiece respirator (without an 
exhalation valve)  (i.e., the HCP 
should not wear both a 
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Component Recommendation(s) Comments 
facemask and respirator at the 
same time.) When respirator use 
is no longer needed, the HCP 
should put a facemask back on 





 Establish procedures for monitoring managing 
and training visitors. 
 Limit visitors to those who are essential for the 
patient’s wellbeing and care. 
 Visits should be scheduled and controlled to 
allow for: 
o Screening of symptoms for acute 
respiratory illness before entering the 
hospital and upon arrival to hospital 
o Facilities to evaluate risk to the health of 
the visitor (e.g., visitor might have 
underlying illness putting them at higher 
risk for MERS-CoV) and ability to comply 
with precautions 
o Facilities to provide instruction, before 
entry into the patient care area on hand 
hygiene, limiting surfaces touched, and 
use of PPE according to the current 
facility policy while in the patients room 
o Facilities should consider tracking (e.g., 
logbook) of all visitors who enter patient 
rooms 
o Visitors should not be present during 
aerosol-generating procedures 
o Visitors should be instructed to limit 
their movement within the facility. 
 Visitors who have been in contact 
with the MERS-CoV patient before 
and during hospitalization are a 
possible source of MERS-CoV for 
other patients, visitors, and staff. 
 
Preparedness 
To aid providers and facilities, CDC has developed two checklists that identify key actions that can be taken now 
to enhance preparedness for MERS-CoV infection control.  
 Healthcare Providers Preparedness Checklist: 
http://www.cdc.gov/coronavirus/mers/preparedness/checklist-provider-preparedness.html 
 Healthcare Facility Preparedness Checklist: 
http://www.cdc.gov/coronavirus/mers/preparedness/checklist-facility-preparedness.html 
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Interim Home Care and Isolation Guidance 
CDC has developed interim guidance for local and state health departments, infection prevention and control 
professionals, healthcare providers, and healthcare workers who are coordinating the home care and isolation 
of ill people who are being evaluated for MERS-CoV infection. 
 Interim Home Care and Isolation Guidance for MERS-CoV: 
http://www.cdc.gov/coronavirus/mers/hcp/home-care.html 
Important Links 
 Respirator Trusted-Source Information: 
http://www.cdc.gov/niosh/npptl/topics/respirators/disp_part/RespSource.html 
 Respirator Fact Sheet:  
http://www.cdc.gov/niosh/npptl/topics/respirators/factsheets/respsars.html 
 
